Amgen reports more Kyprolis data

Amgen Inc. (NASDAQ:AMGN) for the first time reported data from secondary endpoints in the Phase III ASPIRE trial of Kyprolis carfilzomib plus Revlimid lenalidomide and low-dose dexamethasone to treat relapsed multiple myeloma (MM). The company said overall survival data are still not yet mature but did report that the three-drug combo showed a positive trend versus Revlimid plus low-dose dexamethasone.

On other secondary endpoints, ORR was 87.1% for Kyprolis plus Revlimid and low-dose dexamethasone vs. 66.7% for Revlimid and low-dose dexamethasone (one-sided p=0.0001, two-sided p<0.001). Also, median duration of response was 28.6 months for the three drugs vs. 21.2 months for the two-drug control combo. ...